Literature DB >> 6323478

Analysis of the catalytic domain of phosphotransferase activity of two avian sarcoma virus-transforming proteins.

J S Brugge, D Darrow.   

Abstract

Proteolytic digestion of the transforming protein of Rous sarcoma virus (pp60src) with trypsin, chymotrypsin, or thermolysin generated a 29,000-dalton fragment representing the carboxyl half of this molecule. This proteolytic fragment was able to phosphorylate pp60src-specific immunoglobulin as well as exogenous substrates such as angiotensin, casein, and tubulin. When quantitated on a molar basis, the protease-resistant fragment of pp60src had a greater specific activity than the intact enzyme. Digestion of pp90yes, the transforming protein of Y73 sarcoma virus with these proteases yielded a peptide of similar molecular weight which was capable of autophosphorylation as well as the phosphorylation of exogenous substrates. The proteolytic fragments of both pp60src and pp90yes displayed the same strict specificity for phosphorylation of tyrosine as the intact enzymes. These results indicate that the 29,000-dalton carboxyl end of pp60src and pp90yes can function independently as phosphotransferases and indicate that the catalytic domains of these molecules have a conformation which confers protection against limited conditions of proteolysis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323478

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

Review 1.  The discovery of modular binding domains: building blocks of cell signalling.

Authors:  Bruce J Mayer
Journal:  Nat Rev Mol Cell Biol       Date:  2015-09-30       Impact factor: 94.444

2.  The common src homology region 2 domain of cytoplasmic signaling proteins is a positive effector of v-fps tyrosine kinase function.

Authors:  C A Koch; M Moran; I Sadowski; T Pawson
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

3.  Mutagenic analysis of the v-crk oncogene: requirement for SH2 and SH3 domains and correlation between increased cellular phosphotyrosine and transformation.

Authors:  B J Mayer; H Hanafusa
Journal:  J Virol       Date:  1990-08       Impact factor: 5.103

4.  The noncatalytic src homology region 2 segment of abl tyrosine kinase binds to tyrosine-phosphorylated cellular proteins with high affinity.

Authors:  B J Mayer; P K Jackson; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

5.  Inhibition of the tyrosine kinase activity of v-src, v-fgr, and v-yes gene products by a monoclonal antibody which binds both amino and carboxy peptide fragments of pp60v-src.

Authors:  D J McCarley; J T Parsons; D C Benjamin; S J Parsons
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

6.  Identification of Src, Fyn, and Lyn SH3-binding proteins: implications for a function of SH3 domains.

Authors:  Z Weng; S M Thomas; R J Rickles; J A Taylor; A W Brauer; C Seidel-Dugan; W M Michael; G Dreyfuss; J S Brugge
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

7.  Site-directed mutagenesis of the SH2- and SH3-coding domains of c-src produces varied phenotypes, including oncogenic activation of p60c-src.

Authors:  H Hirai; H E Varmus
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

8.  Deletions and insertions within an amino-terminal domain of pp60v-src inactivate transformation and modulate membrane stability.

Authors:  H C Wang; J T Parsons
Journal:  J Virol       Date:  1989-01       Impact factor: 5.103

9.  The membrane-binding domain and myristylation of p60v-src are not essential for stimulation of cell proliferation.

Authors:  G Calothy; D Laugier; F R Cross; R Jove; T Hanafusa; H Hanafusa
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

10.  Effects of SH2 and SH3 deletions on the functional activities of wild-type and transforming variants of c-Src.

Authors:  C Seidel-Dugan; B E Meyer; S M Thomas; J S Brugge
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.